Furthermore, miR-27b inhibits the invasion and growth of CRC tumors in vivo through inhibition of Src and FAK activation, by downregulating the expression of PXN, ARFGEF1, Rab14 and ADAM19, which are the miR-27b targets. Here, SRC is linked to colorectal carcinoma.